a Department of Obstetrics and Gynecology, Division of Molecular Oncology , University Medical Center , Mainz , Germany.
Expert Opin Investig Drugs. 2019 Jan;28(1):1-5. doi: 10.1080/13543784.2019.1552255. Epub 2018 Dec 1.
Triple-negative breast cancer (TNBC) is associated with poor prognosis and limited treatment options. However, TNBC is known to be more immunogenic compared to other breast cancer subtypes, with tumor-infiltrating lymphocytes playing an important prognostic and predictive role. Furthermore, TNBC has a higher level of programmed cell death-ligand 1 (PD-L1) expression. Therapeutic blockade of PD-L1 using atezolizumab is thus expected to activate and enhance tumor-specific T-cell responses, resulting in improved anti-tumor activity. Areas covered: This review summarizes the development and the impact of the PD-L1 inhibitor atezolizumab in advanced TNBC; it examines the mechanism of action, pharmacokinetics and the available preclinical and clinical data. Expert opinion: Atezolizumab, a novel immune checkpoint inhibitors targeting PD-L1, is an effective and well-tolerated treatment option for metastatic TNBC. In general, TNBC has a high unmet medical need, hence the clinical development of atezolizumab should continue, particularly for TNBC. Indeed, atezolizumab has the potential to substantially augment the therapeutic armamentarium for TNBC. This should lead to improved immunotherapeutic strategies and the enhancement of the outcome for this group of breast cancer patients.
三阴性乳腺癌（TNBC）与预后不良和治疗选择有限相关。然而，与其他乳腺癌亚型相比，TNBC 被认为具有更高的免疫原性，肿瘤浸润淋巴细胞在预后和预测中发挥重要作用。此外，TNBC 程序性细胞死亡配体 1（PD-L1）的表达水平更高。因此，使用阿替利珠单抗阻断 PD-L1 有望激活和增强肿瘤特异性 T 细胞反应，从而提高抗肿瘤活性。
本综述总结了 PD-L1 抑制剂阿替利珠单抗在晚期 TNBC 中的开发和影响；它检查了作用机制、药代动力学和可用的临床前和临床数据。
阿替利珠单抗是一种新型的针对 PD-L1 的免疫检查点抑制剂，是转移性 TNBC 的一种有效且耐受良好的治疗选择。一般来说，TNBC 存在着高度未满足的医疗需求，因此阿替利珠单抗的临床开发应继续进行，特别是针对 TNBC。事实上，阿替利珠单抗有可能大大增强 TNBC 的治疗武器库。这将导致免疫治疗策略的改进，并提高这组乳腺癌患者的治疗效果。
